Capricor Therapeutics (CAPR) stock price, revenue, and financials

Capricor Therapeutics market cap is $73.9 m, and annual revenue was $310.25 k in FY 2020

$73.9 M

CAPR Mkt cap, 13-May-2022

$40.8 K

Capricor Therapeutics Revenue Q1, 2021
Capricor Therapeutics Net income (Q1, 2021)-5.2 M
Capricor Therapeutics EBIT (Q1, 2021)-5.2 M
Capricor Therapeutics Cash, 31-Mar-202141.9 M
Capricor Therapeutics EV32.3 M
Get notified regarding key financial metrics and revenue changes at Capricor TherapeuticsLearn more
Banner background

Capricor Therapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.4m195.5k503.2k4.8m5.5m4.0m2.7m1.7m1.0m310.3k

Revenue growth, %

851%15%(28%)

R&D expense

4.1m1.0m5.2m7.8m13.8m16.0m10.8m12.1m5.1m8.5m

General and administrative expense

2.1m1.6m2.2m3.0m4.4m4.9m4.8m4.9m3.6m5.5m

Operating expense total

6.3m2.6m7.4m10.8m18.1m21.0m15.5m17.0m8.7m14.0m

EBIT

(4.9m)(2.4m)(6.9m)(6.0m)(12.6m)(17.0m)(12.9m)(15.3m)(7.7m)(13.7m)

EBIT margin, %

(362%)(1248%)(1372%)(126%)(229%)(425%)(482%)(917%)(770%)(4413%)

Interest expense

14.4k58.1k245.5k1.8m15.3m

Interest income

6.0k1.2k1.9k3.1k14.4k38.5k136.0k94.8k32.9k

Income tax expense

Net Income

(4.9m)(1.9m)(8.9m)(6.2m)(12.9m)(18.8m)2.4m(15.2m)(7.6m)(13.7m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

346.0k813.0k195.5k1.0m1.0m1.3m1.8m1.3m1.3m1.2m1.1m746.8k880.8k996.5k313.3k400.1k404.0k219.2k230.5k410.4k142.1k185.7k49.9k40.8k

R&D expense

702.9k1.5m465.4k332.5k179.1k62.6k36.5k1.4m1.9m2.0m3.8m3.4m3.2m4.3m4.3m4.7m3.3m3.1m1.9m2.7m3.4m3.1m1.8m1.6m1.2m1.9m3.3m

General and administrative expense

523.3k499.3k500.0k442.0k397.2k262.5k384.6k852.3k665.7k819.7k1.4m926.3k972.8k1.1m1.4m1.3m1.2m1.2m1.1m1.4m1.2m1.3m976.5k831.9k912.0k1.1m1.6m1.9m

Operating expense total

1.2m2.0m965.4k774.4k576.3k325.1k421.1k2.2m2.5m2.8m5.2m4.4m4.2m5.4m5.7m6.0m4.4m4.4m3.0m4.1m4.6m4.4m2.8m2.5m912.0k2.3m3.5m5.2m

EBIT

(880.2k)(1.2m)(769.9k)(774.4k)(576.3k)(325.1k)(421.1k)(1.2m)(1.5m)(1.5m)(3.4m)(3.1m)(2.9m)(4.2m)(4.6m)(5.2m)(3.6m)(3.4m)(2.6m)(3.7m)(4.2m)(4.2m)(2.6m)(2.1m)(1.6m)(2.1m)(3.5m)(5.2m)

EBIT margin, %

(254%)(142%)(394%)(114%)(142%)(114%)(191%)(237%)(217%)(347%)(408%)(702%)(405%)(339%)(842%)(921%)(1031%)(1903%)(1109%)(503%)(1146%)(1135%)(6995%)(12645%)

Interest expense

295.012.3k2.0k421.5k13.0k74.0k53.5k58.9k61.5k61.7k55.6k76.5k93.3k101.0k93.5k97.3k

Interest income

1.0k1.9k244.0596.0309.040.0104.0153.01.2k1.2k275.0156.010.5k427.05.4k4.3k12.1k10.4k14.7k39.5k35.8k37.8k22.0k21.1k22.7k3.7k9.2k

Net Income

(880.5k)(1.1m)(771.9k)(352.9k)(566.2k)(482.8k)(597.6k)(1.2m)(1.5m)(1.5m)(3.5m)(3.1m)(2.9m)(4.3m)(4.7m)(5.3m)(3.7m)(3.5m)(2.7m)(3.7m)(4.1m)(4.1m)(2.5m)(2.0m)(1.6m)(2.1m)(3.5m)(5.2m)

Capricor Therapeutics Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

3.3m2.6m435.7k777.2k282.5k285.0k229.2k71.0k13.0m11.6m9.8m6.9m5.0m4.2m11.8m8.9m18.0m2.8m8.3m8.9m7.2m6.3m4.4m7.2m5.9m6.8m13.2m36.3m41.9m

Prepaid Expenses

379.9k420.7k220.4k164.7k155.8k112.7k60.1k38.0k169.6k123.1k105.1k203.0k130.7k92.5k321.4k239.3k118.2k398.2k239.3k190.3k522.3k388.1k426.4k425.9k375.4k129.2k434.0k249.9k736.4k

Current Assets

3.6m3.0m656.1k941.8k438.3k404.3k289.3k109.0k14.0m16.4m14.2m25.4m21.6m17.7m14.9m11.8m22.4m13.5m13.6m15.2m14.6m13.5m11.4m7.9m6.6m7.3m13.8m36.6m42.6m

PP&E

12.7k10.9k8.0k6.4k4.9k1.2k994.0828.0163.5k204.0k224.5k253.8k263.1k332.1k345.0k355.3k351.5k411.9k399.0k394.0k535.2k507.4k622.3k541.7k506.7k474.7k410.9k486.8k838.7k

Total Assets

3.7m3.1m716.0k1.0m495.2k415.3k294.8k114.4k16.0m18.4m16.3m27.5m23.7m19.9m17.0m13.9m24.5m14.1m14.2m15.8m15.4m14.3m12.2m8.6m7.3m7.9m14.3m37.1m43.5m

Accounts Payable

237.8k504.3k327.2k121.7k210.1k249.4k397.6k339.2k1.5m1.7m1.6m2.7m2.7m2.3m3.2m2.9m3.9m2.5m2.2m1.3m1.4m1.2m1.7m1.5m1.5m947.6k1.3m1.8m3.5m

Short-term debt

191.0k258.5k326.8k33.6k34.6k35.7k62.1k74.3k86.5k110.9k123.1k135.2k159.6k171.8k184.0k177.5k188.3k220.7k231.5k242.4k139.9k282.7k

Current Liabilities

436.3k717.8k485.3k267.1k287.1k649.1k1.0m1.2m6.3m6.5m6.2m7.5m6.9m6.5m7.3m6.2m6.7m3.3m16.6m16.7m1.5m1.3m1.9m1.5m1.6m960.7k1.3m1.9m3.8m

Long-term debt

178.2k35.5k

Non-Current Liabilities

15.0m14.6m12.6m12.3m11.4m10.7m12.8m17.8m18.0m4.2m3.4m3.4m3.4m3.4m3.4m3.4m3.4m3.4m3.6m3.4m

Total Debt

191.0k258.5k326.8k33.6k34.6k35.7k62.1k74.3k86.5k110.9k123.1k135.2k159.6k171.8k184.0k177.5k188.3k220.7k231.5k242.4k318.2k318.2k

Total Liabilities

457.9k468.0k1.1m1.5m1.7m17.6m21.5m20.8m20.1m19.1m18.0m18.1m19.0m24.4m21.3m20.8m20.1m4.9m4.7m5.3m4.9m4.9m4.3m4.7m5.5m7.2m

Common Stock

39.7k39.7k39.7k43.1k43.1k43.1k43.1k43.5k11.7k11.7k11.7k16.2k16.2k16.3k18.0k18.0k21.4k21.4k22.6k25.1k28.0k30.0k30.7k33.7k3.5k4.2k9.2k19.7k22.8k

Preferred Stock

Additional Paid-in Capital

45.2m45.5m45.8m46.4m46.5m46.5m46.5m46.5m15.6m15.7m15.9m33.1m33.4m33.7m38.3m39.0m49.5m50.4m54.5m59.5m65.7m68.9m70.4m73.0m73.7m76.5m86.0m111.6m129.5m

Retained Earnings

(42.0m)(43.2m)(45.6m)(45.9m)(46.5m)(47.2m)(47.8m)(48.1m)(25.8m)(28.9m)(31.8m)(39.4m)(44.1m)(49.5m)(57.6m)(61.1m)(63.9m)(55.2m)(59.3m)(63.5m)(69.3m)(71.3m)(72.9m)(76.5m)(79.9m)(93.2m)

Total Equity

3.3m2.4m230.7k542.3k27.2k(642.7k)(1.2m)(1.6m)(1.7m)(3.1m)(4.5m)7.3m4.6m1.9m(1.1m)(5.1m)49.1k(7.2m)(6.6m)(4.3m)10.5m9.6m7.0m3.7m2.4m3.6m9.6m31.7m36.4m

Financial Leverage

1.1 x1.3 x3.1 x1.8 x18.2 x-0.6 x-0.2 x-0.1 x-9.6 x-6 x-3.6 x3.8 x5.2 x10.3 x-15.7 x-2.7 x498.1 x-2 x-2.2 x-3.7 x1.5 x1.5 x1.8 x2.3 x3.1 x2.2 x1.5 x1.2 x1.2 x

Capricor Therapeutics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(4.9m)(1.9m)(8.9m)(6.2m)(12.9m)(18.8m)2.4m(15.2m)(7.6m)(13.7m)

Depreciation and Amortization

7.5k6.3k26.9k41.9k110.9k125.7k144.2k157.7k172.0k143.9k

Accounts Payable

105.5k(254.9k)974.7k70.3k831.2k508.3k(1.5m)(347.4k)(273.2k)1.8m

Cash From Operating Activities

(4.6m)(2.2m)(6.1m)958.6k(10.8m)(15.8m)(14.2m)(13.9m)(6.8m)(10.1m)

Purchases of PP&E

(2.0k)(56.1k)(186.4k)(129.7k)(192.0k)(32.2k)(316.5k)(547.6k)

Capital Expenditures

(21.5k)(1.8k)

Cash From Investing Activities

(2.0k)141.0k(8.1m)(5.2m)5.0m4.7m(3.0m)5.4m

Short-term Borrowings

Cash From Financing Activities

2.3m1.2m5.2m16.5m18.6m11.6m6.9m9.2m33.4m

Net Change in Cash

(2.3m)(992.5k)1.6m6.3m(2.5m)(2.4m)2.3m(2.3m)(645.8k)28.8m

Interest Paid

2.7k1.3k

Income Taxes Paid

Free Cash Flow

(10.8m)(15.8m)(14.2m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(2.1m)(3.2m)(771.9k)(1.1m)(1.7m)(482.8k)(1.1m)(1.4m)(1.2m)(2.7m)(4.3m)(3.5m)(6.6m)(9.5m)(4.3m)(9.0m)(14.3m)(3.7m)(7.1m)(9.9m)(3.7m)(7.8m)(11.9m)(2.5m)(4.6m)(6.2m)(2.1m)(5.6m)(5.2m)

Depreciation and Amortization

4.1k5.9k1.8k3.4k4.8k1.0k1.2k1.4k6.5k16.2k28.4k24.8k51.0k79.8k31.6k65.1k91.8k38.8k76.1k109.6k34.1k73.0k114.4k43.3k86.4k129.2k33.0k65.6k50.1k

Accounts Payable

(94.6k)172.0k(110.7k)(316.1k)(227.8k)66.4k214.7k156.3k12.1k176.8k106.6k1.0m979.6k609.4k693.5k393.1k1.4m(533.0k)(861.0k)(1.8m)(87.9k)(289.9k)247.5k314.0k371.7k(201.2k)420.6k879.6k744.6k

Cash From Operating Activities

(2.4m)(3.1m)(603.5k)(1.5m)(2.0m)(144.2k)(200.0k)(358.2k)11.3m5.3m3.1m(2.1m)(3.9m)(7.2m)(4.2m)(9.1m)(11.6m)(4.7m)(8.4m)(11.6m)(3.4m)(7.1m)(10.1m)(1.6m)(3.4m)(5.0m)(1.2m)(3.2m)(3.3m)

Purchases of PP&E

(92.9k)(116.5k)(146.7k)(27.5k)(50.8k)(124.4k)(45.8k)(75.7k)(86.4k)(3.1k)(15.8k)(32.2k)(186.4k)(186.6k)(332.1k)(107.5k)(36.9k)

Capital Expenditures

(23.7k)(23.7k)(9.5k)(9.5k)(21.5k)(1.8k)(1.8k)

Cash From Investing Activities

(163.3k)(234.4k)(15.5m)(15.5m)(13.1m)5.4m5.4m5.4m4.0m9.0m8.0m1.8m1.8m1.7m3.0m3.0m3.0m6.0m5.9m(36.9k)

Short-term Borrowings

Cash From Financing Activities

2.3m2.3m1.2m1.2m382.5k382.5k382.5k4.7m5.2m16.5m16.5m16.5m4.9m6.9m18.6m3.9m8.6m2.5m5.3m6.3m1.4m2.0m4.6m4.5m29.7m12.6m

Net Change in Cash

(118.3k)(770.8k)(603.5k)(262.0k)(756.7k)238.3k182.5k24.3k11.2m9.9m8.1m(1.1m)(3.0m)(3.8m)6.2m3.3m12.5m(675.3k)4.5m5.0m906.6k(11.4k)(2.1m)2.8m1.6m2.5m9.3m32.4m9.2m

Interest Paid

1.3k1.3k

Income Taxes Paid

Free Cash Flow

5.3m3.1m(2.1m)(3.9m)(7.2m)(4.2m)(9.1m)(11.6m)(8.4m)(11.6m)

Capricor Therapeutics Ratios

USDQ2, 2011

Financial Leverage

1.1 x